IP Library › Granted Patent US 11,641,087
Granted Patent B2
US 11,641,087 · App. 17/148,120 · Granted May 2, 2023

Acquisition of interferometric recordings of brain and neuron activity by coherent microwave probe with therapeutic activation, inactivation, or ablation of molecular, neuronal or brain targets

Inventors: Emad N. Eskandar (Swampscott, MA); James Joseph Cohen (Wenham, MA)
Assignee: Emad Eskandar
H01S1/04A61B18/1815A61B90/36A61N5/045H01S1/005H01S1/02H01S1/06H01S4/00A61B2018/0016A61B2018/00446A61B2018/00577A61B2018/1861A61B2090/374A61B2090/3762A61N2005/027
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,641,087
App. No.
17/148,120
Granted
May 2, 2023
Kind
B2
Abstract

Low power MASER (Microwave Amplification by Stimulated Emission of Radiation) radiation is used to non-invasively record molecular activity in a biological object such as a brain. Low power MASER radiation is also used to neuromodulate molecular targets via Rabi coupling, resulting for example in conformational and function change in specific molecular targets such as ligand-gated ion channels, voltage-gated ion channels, G-proteins, or dopamine receptors. The method can be used to change the energy state of targeted molecules via energization or enervation, or to ablate targeted molecules.

Claims (16)

1. A method of activity mapping using a MASER diffraction-limited interferometer, the method comprising the steps of:

emitting a beam of coherent MASER radiation by an emitter array and passing the emitted beam through a collimator;

splitting of the collimated MASER beam into a probe beam and a reference beam;

passing the probe beam through a head and a brain, spinal column and spinal cord, or other biological parts of a patient to create a post-engagement beam while simultaneously passing the reference beam through a uniform substance resulting in a delay of the reference beam similar to that of the probe beam caused by the head or other body part of the patient in order to generate a lagged reference beam;

combining the lagged reference beam and the post-engagement beam to create a convolved beam characterized by a time-shifting interference pattern;

detecting the time-shifting interference pattern in the convolved beam by a detector array;

de-convolving the interference pattern to quantify changes in phase, modulation, amplitude, and lag between the post-engagement beam and the lagged reference beam to generate a holographic perspective map;

populating a voxel map with the processed data for the slice of time from the given holographic perspective and repeating this step from multiple holographic perspectives in accordance with a synthetic aperture algorithm;

associating the voxel map with an image generated by an MRI or CT scan to create a three-dimensional energy activity map for the given time slice.

2. The method in claim 1 wherein the activity map identifies one or more of the following: inferred changes to the conformation and energy states of saccharides including glucose, peptide neurotransmitters including glutamate, acetylcholine, GABA, dopamine, or serotonin, trans-membrane ion channels and receptors including voltage-gated ion channels, ligand-gated ion channels, or G-protein coupled receptors, reflecting changes in membrane potential or firing of action potentials in neuronal dendrites, soma, and axons.

3. The method in claim 1 wherein the activity map identifies changes associated with the neuronal firing of action potentials.

4. The method in claim 1 wherein the activity map identifies increases or decreases in glucose metabolism.

5. The method in claim 1 wherein the activity map identifies activity levels or conformational changes of g-protein coupled receptors.

6. The method in claim 1 wherein the activity map identifies activity levels or conformational changes of ligand-gated glutamate receptors.

7. The method in claim 1 wherein the activity map identifies activity levels or conformational changes in voltage-gated ion channels.

8. The method in claim 1 , wherein the activity map identifies the activity or conformational changes of IL-13RA2 receptor and EphA2 receptors that are over-expressed in primary brain tumors.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2025
From: ESKANDAR, EMAD
To: NEURADAPTIVE, INC.
Reel/Frame 069866/0726 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2022
From: CEROMAZE INC.
To: ESKANDAR, EMAD
Reel/Frame 062021/0197 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2021
From: ESKANDAR, EMAD N.; COHEN, JAMES JOSEPH
To: CEROMAZE INC.
Reel/Frame 055092/0329 →
Continuity (2)
Provisional Application 62961263 · Jan 15, 2020
Related Publication 20210212764A1 · Jul 15, 2021